Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
Earnings for Mereo BioPharma Group plc (MREO)
Earnings in 2023 (TTM): $-29,998,000
According to Mereo BioPharma Group plc's latest financial reports the company's current earnings (TTM) are $-29,998,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Mereo BioPharma Group plc
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-29,998,000 | $-29,466,000 |
| 2022 | $-36,093,000 | $-34,196,000 |
| 2021 | $14.24 M | $12.73 M |
| 2020 | $-166,450,000 | $-163,628,000 |
| 2019 | $-41,118,000 | $-34,844,000 |
| 2018 | $-37,306,120 | $-32,028,740 |
| 2017 | $-46,951,138 | $-38,799,054 |
| 2016 | $-33,721,551 | $-28,390,280 |